Organization Profile

You just read:

Oncolytics Biotech Inc. Announces Positive Top Line REOLYSIN® Data for First Endpoint in Randomized Phase III Study in Head and Neck Cancers

News provided by

Oncolytics Biotech Inc.

Dec 13, 2012, 06:30 ET